Acquire the license to the best health content in the world
Contact Us

Silodosin Found to Reduce Chronic Prostatitis Symptoms

Silodosin taken daily for 12 weeks relieves CP/CPPS symptoms and improves quality of life

WEDNESDAY, June 29 (HealthDay News) -- Silodosin may provide symptomatic relief and improve quality of life for patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), according to a study published in the July issue of The Journal Of Urology.

J. Curtis Nickel, M.D., from Kingston General Hospital in Canada, and colleagues compared the efficacy and safety of two doses of silodosin with that of placebo in 151 men, with an average age of 48 years, with moderate to severe abacterial CP/CPPS not previously treated with α-blockers. Participants had a total National Institutes of Health Chronic Prostatitis Symptom Index score (NIH-CPSI) of 15 or greater and a NIH-CPSI pain score of eight or greater. A total of 52 participants were randomly allocated to receive 4 mg of silodosin, 45 to receive 8 mg of silodosin, and 54 to receive placebo once daily for 12 weeks. The change in total NIH-CPSI score from baseline to the end of 12 weeks was the main outcome measured.

The investigators found that, compared to placebo, treatment with 4 mg silodosin correlated with a significant reduction in total NIH-CPSI score, including a decrease in urinary symptoms and quality of life subscores. Medical Outcomes Study Short Form-12 physical component scores were also significantly increased with 4 mg silodosin treatment (P = 0.0492). Moderate or marked improvement during the global response assessment was reported by 56 percent of patients receiving 4 mg silodosin in contrast to 29 percent receiving placebo. Silodosin 8 mg did not confer additional treatment benefits.

"Silodosin 4 mg relieved symptoms and improved quality of life in men with CP/CPPS, but its efficacy requires confirmation in additional studies," the authors write.

Several of the study authors disclosed financial relationships with the pharmaceutical industry, including Watson Laboratories Inc., which funded the study.

Abstract
Full Text

Physician's Briefing